A new study shows that blocking a molecule that disrupts the immune system led to 50% reduction of multiple sclerosis in a mouse model of the disease.

Share on Pinterest There is currently no cure for MS, which in many countries, is the leading cause of nontraumatic disability in young adults.

Writing in the Annals of Neurology, researchers from the University of Montreal in Canada describe how they discovered a molecule called MCAM (Melanoma Cell Adhesion Molecule) allows white blood cells to cross the blood-brain barrier and enter the central nervous system where they are free to cause the nerve damage seen in multiple sclerosis.

In their paper the researchers describe promising results in lab tests and a mouse model of the disease where they blocked MCAM. They say a drug that does this in humans could delay onset of multiple sclerosis and significantly slow its progression.

Lead author Alexandre Prat, a neurosciences professor at Montreal, says:

“We believe we have identified the first therapy that will impact the quality of life of people with multiple sclerosis by significantly reducing the disability and the disease’s progression.”

There is no cure for multiple sclerosis (MS), a progressive, disabling neurological disease that leads to paralysis, loss of vision, numbness and difficulty with balance and walking.

In many countries, MS is the leading cause of nontraumatic disability in young adults. While some people with MS experience little disability during their lifetime, as many as 60% may be struggling to walk unaided 20 years after onset.

It is estimated that as many as 2.3 million people worldwide are affected by MS. In Canada, where the study took place, the disease affects nearly 75,000 people.